{
    "nct_id": "NCT02910739",
    "title": "A Two-Part, Open-Label Study to Investigate the Single-Dose Pharmacokinetics of MK-8931 When Administered to Subjects With Mild and Moderate Hepatic Insufficiency",
    "status": "COMPLETED",
    "last_update_time": "2018-02-07",
    "description_brief": "This study consists of Part I and an optional Part II. The purpose of Part I is to compare the plasma pharmacokinetics of verubecestat (MK-8931) following administration of a single oral dose of 40 mg MK-8931 to participants with moderate hepatic insufficiency (HI) to that of healthy matched controls. An interim safety and pharmacokinetic analysis on the basis of Part I will be performed in order to support the decision to continue with the optional Part II. If a decision to continue with Part II is made, participants with mild HI will be enrolled to receive a single oral dose of 40mg MK-8931. If any healthy participants from Part I do not meet the matching criteria for Part II additional healthy participants will be enrolled.",
    "description_detailed": "N/A",
    "phase": [
        "PHASE1"
    ],
    "study_type": "INTERVENTIONAL",
    "primary_purpose": "TREATMENT",
    "results": {
        "participantFlowModule": {
            "preAssignmentDetails": "Per protocol, this study was divided into Part I and an optional Part II, with Part II initiating only after interim analysis (IA) of Part I. Following Part I IA, the pharmacokinetic (PK) criterion necessary to initiate enrollment for Part II was not met. As a result, the study was completed normally without enrollment into the optional Part II.",
            "groups": [
                {
                    "id": "FG000",
                    "title": "Part I: MK-8931 40 mg in Moderate HI Participants",
                    "description": "Single oral dose of MK-8931 (40 mg tablet) in participants with moderate Hepatic Insufficiency (HI) in fasted state (Part I)"
                },
                {
                    "id": "FG001",
                    "title": "Part I: MK-8931 40 mg in Healthy Participants",
                    "description": "Single oral dose of MK-8931 (40 mg tablet) in healthy matched participants in fasted state (Part I)"
                },
                {
                    "id": "FG002",
                    "title": "Part II: MK-8931 40 mg in Mild HI Participants",
                    "description": "Single oral dose of MK-8931 (40 mg tablet) in participants with mild HI in fasted state (Part II)"
                },
                {
                    "id": "FG003",
                    "title": "Part II: MK-8931 40 mg in Healthy Participants",
                    "description": "Single oral dose of MK-8931 (40 mg tablet) in healthy matched participants in fasted state (Part II)"
                }
            ],
            "periods": [
                {
                    "title": "Overall Study",
                    "milestones": [
                        {
                            "type": "STARTED",
                            "achievements": [
                                {
                                    "groupId": "FG000",
                                    "numSubjects": "8"
                                },
                                {
                                    "groupId": "FG001",
                                    "numSubjects": "8"
                                },
                                {
                                    "groupId": "FG002",
                                    "comment": "Participants were not enrolled in Part II as the PK criterion from the Part I IA was not met.",
                                    "numSubjects": "0"
                                },
                                {
                                    "groupId": "FG003",
                                    "comment": "Participants were not enrolled in Part II as the PK criterion from the Part I IA was not met.",
                                    "numSubjects": "0"
                                }
                            ]
                        },
                        {
                            "type": "COMPLETED",
                            "achievements": [
                                {
                                    "groupId": "FG000",
                                    "numSubjects": "7"
                                },
                                {
                                    "groupId": "FG001",
                                    "numSubjects": "8"
                                },
                                {
                                    "groupId": "FG002",
                                    "comment": "Participants were not enrolled in Part II as the PK criterion from the Part I IA was not met.",
                                    "numSubjects": "0"
                                },
                                {
                                    "groupId": "FG003",
                                    "comment": "Participants were not enrolled in Part II as the PK criterion from the Part I IA was not met.",
                                    "numSubjects": "0"
                                }
                            ]
                        },
                        {
                            "type": "NOT COMPLETED",
                            "achievements": [
                                {
                                    "groupId": "FG000",
                                    "numSubjects": "1"
                                },
                                {
                                    "groupId": "FG001",
                                    "numSubjects": "0"
                                },
                                {
                                    "groupId": "FG002",
                                    "numSubjects": "0"
                                },
                                {
                                    "groupId": "FG003",
                                    "numSubjects": "0"
                                }
                            ]
                        }
                    ],
                    "dropWithdraws": [
                        {
                            "type": "Adverse Event",
                            "reasons": [
                                {
                                    "groupId": "FG000",
                                    "numSubjects": "1"
                                },
                                {
                                    "groupId": "FG001",
                                    "numSubjects": "0"
                                },
                                {
                                    "groupId": "FG002",
                                    "numSubjects": "0"
                                },
                                {
                                    "groupId": "FG003",
                                    "numSubjects": "0"
                                }
                            ]
                        }
                    ]
                }
            ]
        },
        "baselineCharacteristicsModule": {
            "groups": [
                {
                    "id": "BG000",
                    "title": "Part I: MK-8931 40 mg in Moderate HI Participants",
                    "description": "Single oral dose of MK-8931 (40 mg tablet) in participants with moderate HI in fasted state (Part I)"
                },
                {
                    "id": "BG001",
                    "title": "Part I: MK-8931 40 mg in Healthy Participants",
                    "description": "Single oral dose of MK-8931 (40 mg tablet) in healthy matched participants in fasted state (Part I)"
                },
                {
                    "id": "BG002",
                    "title": "Total",
                    "description": "Total of all reporting groups"
                }
            ],
            "denoms": [
                {
                    "units": "Participants",
                    "counts": [
                        {
                            "groupId": "BG000",
                            "value": "8"
                        },
                        {
                            "groupId": "BG001",
                            "value": "8"
                        },
                        {
                            "groupId": "BG002",
                            "value": "16"
                        }
                    ]
                }
            ],
            "measures": [
                {
                    "title": "Age, Continuous",
                    "paramType": "MEAN",
                    "dispersionType": "STANDARD_DEVIATION",
                    "unitOfMeasure": "years",
                    "classes": [
                        {
                            "categories": [
                                {
                                    "measurements": [
                                        {
                                            "groupId": "BG000",
                                            "value": "61.0",
                                            "spread": "6.1"
                                        },
                                        {
                                            "groupId": "BG001",
                                            "value": "61.4",
                                            "spread": "4.8"
                                        },
                                        {
                                            "groupId": "BG002",
                                            "value": "61.2",
                                            "spread": "5.3"
                                        }
                                    ]
                                }
                            ]
                        }
                    ]
                },
                {
                    "title": "Sex: Female, Male",
                    "paramType": "COUNT_OF_PARTICIPANTS",
                    "unitOfMeasure": "Participants",
                    "classes": [
                        {
                            "categories": [
                                {
                                    "title": "Female",
                                    "measurements": [
                                        {
                                            "groupId": "BG000",
                                            "value": "1"
                                        },
                                        {
                                            "groupId": "BG001",
                                            "value": "1"
                                        },
                                        {
                                            "groupId": "BG002",
                                            "value": "2"
                                        }
                                    ]
                                },
                                {
                                    "title": "Male",
                                    "measurements": [
                                        {
                                            "groupId": "BG000",
                                            "value": "7"
                                        },
                                        {
                                            "groupId": "BG001",
                                            "value": "7"
                                        },
                                        {
                                            "groupId": "BG002",
                                            "value": "14"
                                        }
                                    ]
                                }
                            ]
                        }
                    ]
                },
                {
                    "title": "Race (NIH/OMB)",
                    "paramType": "COUNT_OF_PARTICIPANTS",
                    "unitOfMeasure": "Participants",
                    "classes": [
                        {
                            "categories": [
                                {
                                    "title": "American Indian or Alaska Native",
                                    "measurements": [
                                        {
                                            "groupId": "BG000",
                                            "value": "0"
                                        },
                                        {
                                            "groupId": "BG001",
                                            "value": "0"
                                        },
                                        {
                                            "groupId": "BG002",
                                            "value": "0"
                                        }
                                    ]
                                },
                                {
                                    "title": "Asian",
                                    "measurements": [
                                        {
                                            "groupId": "BG000",
                                            "value": "0"
                                        },
                                        {
                                            "groupId": "BG001",
                                            "value": "0"
                                        },
                                        {
                                            "groupId": "BG002",
                                            "value": "0"
                                        }
                                    ]
                                },
                                {
                                    "title": "Native Hawaiian or Other Pacific Islander",
                                    "measurements": [
                                        {
                                            "groupId": "BG000",
                                            "value": "0"
                                        },
                                        {
                                            "groupId": "BG001",
                                            "value": "0"
                                        },
                                        {
                                            "groupId": "BG002",
                                            "value": "0"
                                        }
                                    ]
                                },
                                {
                                    "title": "Black or African American",
                                    "measurements": [
                                        {
                                            "groupId": "BG000",
                                            "value": "1"
                                        },
                                        {
                                            "groupId": "BG001",
                                            "value": "1"
                                        },
                                        {
                                            "groupId": "BG002",
                                            "value": "2"
                                        }
                                    ]
                                },
                                {
                                    "title": "White",
                                    "measurements": [
                                        {
                                            "groupId": "BG000",
                                            "value": "7"
                                        },
                                        {
                                            "groupId": "BG001",
                                            "value": "7"
                                        },
                                        {
                                            "groupId": "BG002",
                                            "value": "14"
                                        }
                                    ]
                                },
                                {
                                    "title": "More than one race",
                                    "measurements": [
                                        {
                                            "groupId": "BG000",
                                            "value": "0"
                                        },
                                        {
                                            "groupId": "BG001",
                                            "value": "0"
                                        },
                                        {
                                            "groupId": "BG002",
                                            "value": "0"
                                        }
                                    ]
                                },
                                {
                                    "title": "Unknown or Not Reported",
                                    "measurements": [
                                        {
                                            "groupId": "BG000",
                                            "value": "0"
                                        },
                                        {
                                            "groupId": "BG001",
                                            "value": "0"
                                        },
                                        {
                                            "groupId": "BG002",
                                            "value": "0"
                                        }
                                    ]
                                }
                            ]
                        }
                    ]
                },
                {
                    "title": "Body Mass Index (BMI)",
                    "paramType": "MEAN",
                    "dispersionType": "FULL_RANGE",
                    "unitOfMeasure": "kg/m^2",
                    "classes": [
                        {
                            "categories": [
                                {
                                    "measurements": [
                                        {
                                            "groupId": "BG000",
                                            "value": "29.688",
                                            "lowerLimit": "20.40",
                                            "upperLimit": "36.10"
                                        },
                                        {
                                            "groupId": "BG001",
                                            "value": "30.313",
                                            "lowerLimit": "27.50",
                                            "upperLimit": "32.60"
                                        },
                                        {
                                            "groupId": "BG002",
                                            "value": "30.000",
                                            "lowerLimit": "20.40",
                                            "upperLimit": "36.10"
                                        }
                                    ]
                                }
                            ]
                        }
                    ]
                }
            ]
        },
        "outcomeMeasuresModule": {
            "outcomeMeasures": [
                {
                    "type": "PRIMARY",
                    "title": "Area Under the Concentration Versus Time Curve of MK-8931 From 0 to Infinity (AUC0-\u221e)",
                    "description": "Blood samples were collected at each pre-specified time point and plasma was isolated for analysis. Plasma MK-8931 concentration was then quantified at each time point to determine AUC0-\u221e, defined as the area under the MK-8931 concentration versus time curve from 0 (predose) extrapolated to infinity after a single oral dose of MK-8931 40 mg. Individual AUC0-\u221e values were natural log (ln) transformed and evaluated with an analysis of covariance (ANCOVA) model containing a categorical factor for participant group (Moderate HI, Healthy Matched Control) and continuous covariates for age and BMI. This ANCOVA model was used to compute a geometric least-squares mean and 95% confidence interval for AUC0-\u221e in each arm.",
                    "populationDescription": "All participants who received the single dose of MK-8931 40 mg, complied with trial protocol, and had blood samples available for the evaluation of AUC0-\u221e. One participant with moderate HI discontinued study prior to collection of samples at 72, 96, and 120 hours post-dose and was excluded from analysis.",
                    "reportingStatus": "POSTED",
                    "paramType": "GEOMETRIC_LEAST_SQUARES_MEAN",
                    "dispersionType": "95% Confidence Interval",
                    "unitOfMeasure": "micromolar(\u00b5M)*hour(hr)",
                    "timeFrame": "Predose and 0.5, 1, 2, 3, 4, 6, 8, 12, 24, 48, 72, 96, and 120 hours after MK-8931 40 mg dose",
                    "groups": [
                        {
                            "id": "OG000",
                            "title": "Part I: MK-8931 40 mg in Moderate HI Participants",
                            "description": "Single oral dose of MK-8931 (40 mg tablet) in participants with moderate HI in fasted state (Part I)"
                        },
                        {
                            "id": "OG001",
                            "title": "Part I: MK-8931 40 mg in Healthy Participants",
                            "description": "Single oral dose of MK-8931 (40 mg tablet) in healthy matched participants in fasted state (Part I)"
                        }
                    ],
                    "denoms": [
                        {
                            "units": "Participants",
                            "counts": [
                                {
                                    "groupId": "OG000",
                                    "value": "7"
                                },
                                {
                                    "groupId": "OG001",
                                    "value": "8"
                                }
                            ]
                        }
                    ],
                    "classes": [
                        {
                            "categories": [
                                {
                                    "measurements": [
                                        {
                                            "groupId": "OG000",
                                            "value": "3.48",
                                            "lowerLimit": "2.85",
                                            "upperLimit": "4.25"
                                        },
                                        {
                                            "groupId": "OG001",
                                            "value": "3.34",
                                            "lowerLimit": "2.77",
                                            "upperLimit": "4.03"
                                        }
                                    ]
                                }
                            ]
                        }
                    ],
                    "analyses": [
                        {
                            "groupIds": [
                                "OG000",
                                "OG001"
                            ],
                            "groupDescription": "Per study protocol, the purpose of this analysis is only to estimate the effect of moderate HI on AUC0-\u221e; no hypothesis testing was planned for this outcome measure.",
                            "nonInferiorityType": "OTHER",
                            "nonInferiorityComment": "The pharmacokinetic condition to initiate Part 2 of the study would be met if the point estimate for the AUC0-\u221e ratio of geometric means (participants with moderate HI / healthy matched control participants) exceeds 1.5.",
                            "paramType": "Geometric least-squares mean ratio (GMR)",
                            "paramValue": "1.04",
                            "ciPctValue": "90",
                            "ciNumSides": "TWO_SIDED",
                            "ciLowerLimit": "0.83",
                            "ciUpperLimit": "1.30",
                            "estimateComment": "GMR = geometric least squares mean (GLSM) for moderate HI participants / GLSM for healthy participants."
                        }
                    ]
                },
                {
                    "type": "PRIMARY",
                    "title": "Maximum Observed Plasma Concentration of MK-8931 (Cmax)",
                    "description": "Blood samples were collected at each pre-specified time point and plasma was isolated for analysis. Plasma MK-8931 concentration was then quantified at each time point to determine Cmax, defined as the maximum plasma concentration of MK-8931 observed following oral dosing. Individual Cmax values were ln-transformed and evaluated with an ANCOVA model containing a categorical factor for participant group (Moderate HI, Healthy Matched Control) and continuous covariates for age and BMI. This ANCOVA model was used to compute a geometric least-squares mean and 95% confidence interval for Cmax in each arm.",
                    "populationDescription": "All participants who received the single dose of MK-8931 40 mg, complied with trial protocol, and had blood samples available for the evaluation of Cmax.",
                    "reportingStatus": "POSTED",
                    "paramType": "GEOMETRIC_LEAST_SQUARES_MEAN",
                    "dispersionType": "95% Confidence Interval",
                    "unitOfMeasure": "nanomolar (nM)",
                    "timeFrame": "Predose and 0.5, 1, 2, 3, 4, 6, 8, 12, 24, and 48 hours after MK-8931 40 mg dose",
                    "groups": [
                        {
                            "id": "OG000",
                            "title": "Part I: MK-8931 40 mg in Moderate HI Participants",
                            "description": "Single oral dose of MK-8931 (40 mg tablet) in participants with moderate HI in fasted state (Part I)"
                        },
                        {
                            "id": "OG001",
                            "title": "Part I: MK-8931 40 mg in Healthy Participants",
                            "description": "Single oral dose of MK-8931 (40 mg tablet) in healthy matched participants in fasted state (Part I)"
                        }
                    ],
                    "denoms": [
                        {
                            "units": "Participants",
                            "counts": [
                                {
                                    "groupId": "OG000",
                                    "value": "8"
                                },
                                {
                                    "groupId": "OG001",
                                    "value": "8"
                                }
                            ]
                        }
                    ],
                    "classes": [
                        {
                            "categories": [
                                {
                                    "measurements": [
                                        {
                                            "groupId": "OG000",
                                            "value": "154",
                                            "lowerLimit": "116",
                                            "upperLimit": "206"
                                        },
                                        {
                                            "groupId": "OG001",
                                            "value": "144",
                                            "lowerLimit": "108",
                                            "upperLimit": "192"
                                        }
                                    ]
                                }
                            ]
                        }
                    ],
                    "analyses": [
                        {
                            "groupIds": [
                                "OG000",
                                "OG001"
                            ],
                            "groupDescription": "Per study protocol, the purpose of this analysis is only to estimate the effect of moderate HI on Cmax; no hypothesis testing was planned for this outcome measure.",
                            "nonInferiorityType": "OTHER",
                            "paramType": "GMR",
                            "paramValue": "1.07",
                            "ciPctValue": "90",
                            "ciNumSides": "TWO_SIDED",
                            "ciLowerLimit": "0.77",
                            "ciUpperLimit": "1.50",
                            "estimateComment": "GMR = GLSM for moderate HI participants / GLSM for healthy participants."
                        }
                    ]
                },
                {
                    "type": "PRIMARY",
                    "title": "Area Under the Concentration Versus Time Curve of MK-8931 From 0 to the Time of the Last Quantifiable (Above LLOQ) Sample (AUC0-last)",
                    "description": "Blood samples were collected at each pre-specified time point and plasma was isolated for analysis. Plasma MK-8931 concentration was then quantified at each time point to determine AUC0-last, defined as the area under the MK-8931 concentration versus time curve from 0 (predose) to the time of the last sample with quantifiable MK-8931 (above the lower limit of quantification; LLOQ) after a single oral dose of MK-8931 40 mg. Individual AUC0-last values were ln-transformed and evaluated with an ANCOVA model containing a categorical factor for participant group (Moderate HI, Healthy Matched Control) and continuous covariates for age and BMI. This ANCOVA model was used to compute a geometric least-squares mean and 95% confidence interval for AUC0-last in each arm.",
                    "populationDescription": "All participants who received the single dose of MK-8931 40 mg, complied with trial protocol, and had blood samples available for the evaluation of AUC0-last. One participant with moderate HI discontinued study prior to collection of samples at 72, 96, and 120 hours post-dose and was excluded from analysis.",
                    "reportingStatus": "POSTED",
                    "paramType": "GEOMETRIC_LEAST_SQUARES_MEAN",
                    "dispersionType": "95% Confidence Interval",
                    "unitOfMeasure": "\u00b5M*hr",
                    "timeFrame": "Predose and 0.5, 1, 2, 3, 4, 6, 8, 12, 24, 48, 72, 96, and 120 hours after MK-8931 40 mg dose",
                    "groups": [
                        {
                            "id": "OG000",
                            "title": "Part I: MK-8931 40 mg in Moderate HI Participants",
                            "description": "Single oral dose of MK-8931 (40 mg tablet) in participants with moderate HI in fasted state (Part I)"
                        },
                        {
                            "id": "OG001",
                            "title": "Part I: MK-8931 40 mg in Healthy Participants",
                            "description": "Single oral dose of MK-8931 (40 mg tablet) in healthy matched participants in fasted state (Part I)"
                        }
                    ],
                    "denoms": [
                        {
                            "units": "Participants",
                            "counts": [
                                {
                                    "groupId": "OG000",
                                    "value": "7"
                                },
                                {
                                    "groupId": "OG001",
                                    "value": "8"
                                }
                            ]
                        }
                    ],
                    "classes": [
                        {
                            "categories": [
                                {
                                    "measurements": [
                                        {
                                            "groupId": "OG000",
                                            "value": "3.35",
                                            "lowerLimit": "2.72",
                                            "upperLimit": "4.11"
                                        },
                                        {
                                            "groupId": "OG001",
                                            "value": "3.22",
                                            "lowerLimit": "2.66",
                                            "upperLimit": "3.91"
                                        }
                                    ]
                                }
                            ]
                        }
                    ],
                    "analyses": [
                        {
                            "groupIds": [
                                "OG000",
                                "OG001"
                            ],
                            "groupDescription": "Per study protocol, the purpose of this analysis is only to estimate the effect of moderate HI on AUC0-last; no hypothesis testing was planned for this outcome measure.",
                            "nonInferiorityType": "OTHER",
                            "paramType": "GMR",
                            "paramValue": "1.04",
                            "ciPctValue": "90",
                            "ciNumSides": "TWO_SIDED",
                            "ciLowerLimit": "0.82",
                            "ciUpperLimit": "1.31",
                            "estimateComment": "GMR = GLSM for moderate HI participants / GLSM for healthy participants."
                        }
                    ]
                },
                {
                    "type": "PRIMARY",
                    "title": "Area Under the Concentration Versus Time Curve of MK-8931 From 0 to 24 Hours (AUC0-24hr)",
                    "description": "Blood samples were collected at each pre-specified time point and plasma was isolated for analysis. Plasma MK-8931 concentration was then quantified at each time point to determine AUC0-24hr, defined as the area under the MK-8931 concentration versus time curve from 0 (predose) until 24 hours after single oral dosing of MK-8931 40 mg. Individual AUC0-24hr values were ln-transformed and evaluated with an ANCOVA model containing a categorical factor for participant group (Moderate HI, Healthy Matched Control) and continuous covariates for age and BMI. This ANCOVA model was used to compute a geometric least-squares mean and 95% confidence interval for AUC0-24hr in each arm.",
                    "populationDescription": "All participants who received the single dose of MK-8931 40 mg, complied with trial protocol, and had blood samples available for the evaluation of AUC0-24hr.",
                    "reportingStatus": "POSTED",
                    "paramType": "GEOMETRIC_LEAST_SQUARES_MEAN",
                    "dispersionType": "95% Confidence Interval",
                    "unitOfMeasure": "\u00b5M*hr",
                    "timeFrame": "Predose and 0.5, 1, 2, 3, 4, 6, 8, 12 and 24 hours after MK-8931 40 mg dose",
                    "groups": [
                        {
                            "id": "OG000",
                            "title": "Part I: MK-8931 40 mg in Moderate HI Participants",
                            "description": "Single oral dose of MK-8931 (40 mg tablet) in participants with moderate HI in fasted state (Part I)"
                        },
                        {
                            "id": "OG001",
                            "title": "Part I: MK-8931 40 mg in Healthy Participants",
                            "description": "Single oral dose of MK-8931 (40 mg tablet) in healthy matched participants in fasted state (Part I)"
                        }
                    ],
                    "denoms": [
                        {
                            "units": "Participants",
                            "counts": [
                                {
                                    "groupId": "OG000",
                                    "value": "8"
                                },
                                {
                                    "groupId": "OG001",
                                    "value": "8"
                                }
                            ]
                        }
                    ],
                    "classes": [
                        {
                            "categories": [
                                {
                                    "measurements": [
                                        {
                                            "groupId": "OG000",
                                            "value": "1.90",
                                            "lowerLimit": "1.56",
                                            "upperLimit": "2.32"
                                        },
                                        {
                                            "groupId": "OG001",
                                            "value": "1.88",
                                            "lowerLimit": "1.54",
                                            "upperLimit": "2.30"
                                        }
                                    ]
                                }
                            ]
                        }
                    ],
                    "analyses": [
                        {
                            "groupIds": [
                                "OG000",
                                "OG001"
                            ],
                            "groupDescription": "Per study protocol, the purpose of this analysis is only to estimate the effect of moderate HI on AUC0-24hr; no hypothesis testing was planned for this outcome measure.",
                            "nonInferiorityType": "OTHER",
                            "paramType": "GMR",
                            "paramValue": "1.01",
                            "ciPctValue": "90",
                            "ciNumSides": "TWO_SIDED",
                            "ciLowerLimit": "0.80",
                            "ciUpperLimit": "1.27",
                            "estimateComment": "GMR = GLSM for moderate HI participants / GLSM for healthy participants."
                        }
                    ]
                },
                {
                    "type": "PRIMARY",
                    "title": "Plasma Concentration of MK-8931 at 24 Hours (C24hr)",
                    "description": "Blood samples were collected 24 hours following oral dosing of MK-8931 and plasma was isolated for analysis. Plasma MK-8931 concentration was then quantified to determine C24hr, defined as the plasma concentration of MK-8931 at 24 hours after single oral dosing of MK-8931 40 mg. Individual C24hr values were ln-transformed and evaluated with an ANCOVA model containing a categorical factor for participant group (Moderate HI, Healthy Matched Control) and continuous covariates for age and BMI. This ANCOVA model was used to compute a geometric least-squares mean and 95% confidence interval for C24hr in each arm.",
                    "populationDescription": "All participants who received the single dose of MK-8931 40 mg, complied with trial protocol, and had blood samples available for the evaluation of C24hr.",
                    "reportingStatus": "POSTED",
                    "paramType": "GEOMETRIC_LEAST_SQUARES_MEAN",
                    "dispersionType": "95% Confidence Interval",
                    "unitOfMeasure": "nM",
                    "timeFrame": "24 hours after MK-8931 40 mg dose",
                    "groups": [
                        {
                            "id": "OG000",
                            "title": "Part I: MK-8931 40 mg in Moderate HI Participants",
                            "description": "Single oral dose of MK-8931 (40 mg tablet) in participants with moderate HI in fasted state (Part I)"
                        },
                        {
                            "id": "OG001",
                            "title": "Part I: MK-8931 40 mg in Healthy Participants",
                            "description": "Single oral dose of MK-8931 (40 mg tablet) in healthy matched participants in fasted state (Part I)"
                        }
                    ],
                    "denoms": [
                        {
                            "units": "Participants",
                            "counts": [
                                {
                                    "groupId": "OG000",
                                    "value": "8"
                                },
                                {
                                    "groupId": "OG001",
                                    "value": "8"
                                }
                            ]
                        }
                    ],
                    "classes": [
                        {
                            "categories": [
                                {
                                    "measurements": [
                                        {
                                            "groupId": "OG000",
                                            "value": "51.1",
                                            "lowerLimit": "43.6",
                                            "upperLimit": "59.8"
                                        },
                                        {
                                            "groupId": "OG001",
                                            "value": "47.1",
                                            "lowerLimit": "40.2",
                                            "upperLimit": "55.2"
                                        }
                                    ]
                                }
                            ]
                        }
                    ],
                    "analyses": [
                        {
                            "groupIds": [
                                "OG000",
                                "OG001"
                            ],
                            "groupDescription": "Per study protocol, the purpose of this analysis is only to estimate the effect of moderate HI on C24hr; no hypothesis testing was planned for this outcome measure.",
                            "nonInferiorityType": "OTHER",
                            "paramType": "GMR",
                            "paramValue": "1.08",
                            "ciPctValue": "90",
                            "ciNumSides": "TWO_SIDED",
                            "ciLowerLimit": "0.90",
                            "ciUpperLimit": "1.30",
                            "estimateComment": "GMR = GLSM for moderate HI participants / GLSM for healthy participants."
                        }
                    ]
                },
                {
                    "type": "PRIMARY",
                    "title": "Apparent Clearance of MK-8931 After Extravascular Administration (CL/F)",
                    "description": "Geometric mean apparent clearance of MK-8931 after extravascular administration (CL/F) was assessed. Blood samples were collected at each pre-specified time point and plasma was isolated for analysis. Plasma MK-8931 concentration was then quantified at each time point to determine CL/F, defined as the rate of MK-8931 elimination normalized to the bioavailability of MK-8931 in the plasma following oral MK-8931 administration.",
                    "populationDescription": "All participants who received the single dose of MK-8931 40 mg, complied with trial protocol, and had blood samples available for the evaluation of CL/F. One participant with moderate HI discontinued study prior to collection of samples at 72, 96, and 120 hours post-dose and was excluded from analysis.",
                    "reportingStatus": "POSTED",
                    "paramType": "GEOMETRIC_MEAN",
                    "dispersionType": "Geometric Coefficient of Variation",
                    "unitOfMeasure": "Liters/hr",
                    "timeFrame": "Predose and 0.5, 1, 2, 3, 4, 6, 8, 12, 24, 48, 72, 96, and 120 hours after MK-8931 40 mg dose",
                    "groups": [
                        {
                            "id": "OG000",
                            "title": "Part I: MK-8931 40 mg in Moderate HI Participants",
                            "description": "Single oral dose of MK-8931 (40 mg tablet) in participants with moderate HI in fasted state (Part I)"
                        },
                        {
                            "id": "OG001",
                            "title": "Part I: MK-8931 40 mg in Healthy Participants",
                            "description": "Single oral dose of MK-8931 (40 mg tablet) in healthy matched participants in fasted state (Part I)"
                        }
                    ],
                    "denoms": [
                        {
                            "units": "Participants",
                            "counts": [
                                {
                                    "groupId": "OG000",
                                    "value": "7"
                                },
                                {
                                    "groupId": "OG001",
                                    "value": "8"
                                }
                            ]
                        }
                    ],
                    "classes": [
                        {
                            "categories": [
                                {
                                    "measurements": [
                                        {
                                            "groupId": "OG000",
                                            "value": "28.4",
                                            "spread": "26.3"
                                        },
                                        {
                                            "groupId": "OG001",
                                            "value": "29.0",
                                            "spread": "22.7"
                                        }
                                    ]
                                }
                            ]
                        }
                    ]
                },
                {
                    "type": "PRIMARY",
                    "title": "Time to Maximum Observed MK-8931 Plasma Drug Concentration (Tmax)",
                    "description": "Median time to maximum observed MK-8931 plasma drug concentration (Tmax) was assessed. Blood samples were collected at each pre-specified time point and plasma was isolated for analysis. Plasma MK-8931 concentration was then quantified at each time point to determine Tmax, defined as the amount of time required following MK-8931 administration for the plasma concentration of MK-8931 to reach maximum observed concentration.",
                    "populationDescription": "All participants who received the single dose of MK-8931 40 mg, complied with trial protocol, and had blood samples available for the evaluation of Tmax.",
                    "reportingStatus": "POSTED",
                    "paramType": "MEDIAN",
                    "dispersionType": "Full Range",
                    "unitOfMeasure": "hr",
                    "timeFrame": "Predose and 0.5, 1, 2, 3, 4, 6, 8, 12, 24, and 48 hours after MK-8931 40 mg dose",
                    "groups": [
                        {
                            "id": "OG000",
                            "title": "Part I: MK-8931 40 mg in Moderate HI Participants",
                            "description": "Single oral dose of MK-8931 (40 mg tablet) in participants with moderate HI in fasted state (Part I)"
                        },
                        {
                            "id": "OG001",
                            "title": "Part I: MK-8931 40 mg in Healthy Participants",
                            "description": "Single oral dose of MK-8931 (40 mg tablet) in healthy matched participants in fasted state (Part I)"
                        }
                    ],
                    "denoms": [
                        {
                            "units": "Participants",
                            "counts": [
                                {
                                    "groupId": "OG000",
                                    "value": "8"
                                },
                                {
                                    "groupId": "OG001",
                                    "value": "8"
                                }
                            ]
                        }
                    ],
                    "classes": [
                        {
                            "categories": [
                                {
                                    "measurements": [
                                        {
                                            "groupId": "OG000",
                                            "value": "1.00",
                                            "lowerLimit": "0.50",
                                            "upperLimit": "4.00"
                                        },
                                        {
                                            "groupId": "OG001",
                                            "value": "2.00",
                                            "lowerLimit": "0.50",
                                            "upperLimit": "4.00"
                                        }
                                    ]
                                }
                            ]
                        }
                    ]
                },
                {
                    "type": "PRIMARY",
                    "title": "Apparent Terminal Half-Life of MK-8931 (t1/2)",
                    "description": "Geometric mean apparent terminal half-life (t1/2) of MK-8931 was assessed. Blood samples were collected at each pre-specified time point and plasma was isolated for analysis. Plasma MK-8931 concentration was then quantified at each time point to determine t1/2, defined as the time required for the plasma MK-8931 concentration to decrease to 50% of maximum.",
                    "populationDescription": "All participants who received the single dose of MK-8931 40 mg, complied with trial protocol, and had blood samples available for the evaluation of t1/2. One participant with moderate HI discontinued study prior to collection of samples at 72, 96, and 120 hours post-dose and was excluded from analysis.",
                    "reportingStatus": "POSTED",
                    "paramType": "GEOMETRIC_MEAN",
                    "dispersionType": "Geometric Coefficient of Variation",
                    "unitOfMeasure": "hr",
                    "timeFrame": "Predose and 0.5, 1, 2, 3, 4, 6, 8, 12, 24, 48, 72, 96, and 120 hours after MK-8931 40 mg dose",
                    "groups": [
                        {
                            "id": "OG000",
                            "title": "Part I: MK-8931 40 mg in Moderate HI Participants",
                            "description": "Single oral dose of MK-8931 (40 mg tablet) in participants with moderate HI in fasted state (Part I)"
                        },
                        {
                            "id": "OG001",
                            "title": "Part I: MK-8931 40 mg in Healthy Participants",
                            "description": "Single oral dose of MK-8931 (40 mg tablet) in healthy matched participants in fasted state (Part I)"
                        }
                    ],
                    "denoms": [
                        {
                            "units": "Participants",
                            "counts": [
                                {
                                    "groupId": "OG000",
                                    "value": "7"
                                },
                                {
                                    "groupId": "OG001",
                                    "value": "8"
                                }
                            ]
                        }
                    ],
                    "classes": [
                        {
                            "categories": [
                                {
                                    "measurements": [
                                        {
                                            "groupId": "OG000",
                                            "value": "23.0",
                                            "spread": "15.7"
                                        },
                                        {
                                            "groupId": "OG001",
                                            "value": "24.7",
                                            "spread": "9.3"
                                        }
                                    ]
                                }
                            ]
                        }
                    ]
                },
                {
                    "type": "PRIMARY",
                    "title": "Apparent Volume of Distribution of MK-8931 During the Terminal Phase After Extravascular Administration (Vz/F)",
                    "description": "Geometric mean apparent volume of distribution of MK-8931 during the terminal phase after extravascular administration (Vz/F) was assessed. Blood samples were collected at each pre-specified time point and plasma was isolated for analysis. Plasma MK-8931 concentration was then quantified at each time point to determine Vz/F, defined as the total amount of MK-8931 administered normalized to the bioavailability of MK-8931 in the plasma during the terminal phase following oral MK-8931 administration.",
                    "populationDescription": "All participants who received the single dose of MK-8931 40 mg, complied with trial protocol, and had blood samples available for the evaluation of Vz/F. One participant with moderate HI discontinued study prior to collection of samples at 72, 96, and 120 hours post-dose and was excluded from analysis.",
                    "reportingStatus": "POSTED",
                    "paramType": "GEOMETRIC_MEAN",
                    "dispersionType": "Geometric Coefficient of Variation",
                    "unitOfMeasure": "Liters",
                    "timeFrame": "Predose and 0.5, 1, 2, 3, 4, 6, 8, 12, 24, 48, 72, 96, and 120 hours after MK-8931 40 mg dose",
                    "groups": [
                        {
                            "id": "OG000",
                            "title": "Part I: MK-8931 40 mg in Moderate HI Participants",
                            "description": "Single oral dose of MK-8931 (40 mg tablet) in participants with moderate HI in fasted state (Part I)"
                        },
                        {
                            "id": "OG001",
                            "title": "Part I: MK-8931 40 mg in Healthy Participants",
                            "description": "Single oral dose of MK-8931 (40 mg tablet) in healthy matched participants in fasted state (Part I)"
                        }
                    ],
                    "denoms": [
                        {
                            "units": "Participants",
                            "counts": [
                                {
                                    "groupId": "OG000",
                                    "value": "7"
                                },
                                {
                                    "groupId": "OG001",
                                    "value": "8"
                                }
                            ]
                        }
                    ],
                    "classes": [
                        {
                            "categories": [
                                {
                                    "measurements": [
                                        {
                                            "groupId": "OG000",
                                            "value": "940",
                                            "spread": "27.3"
                                        },
                                        {
                                            "groupId": "OG001",
                                            "value": "1030",
                                            "spread": "26.1"
                                        }
                                    ]
                                }
                            ]
                        }
                    ]
                },
                {
                    "type": "SECONDARY",
                    "title": "Number of Participants Experiencing an Adverse Event",
                    "description": "The number of participants experiencing an adverse event (AE) was assessed. An AE is any unfavorable and unintended medical occurrence, symptom, or disease witnessed in a participant, regardless of whether or not a causal relationship with the study treatment can be demonstrated. Further, any worsening of a preexisting condition that is temporally associated with the use of the study treatment is also considered an AE.",
                    "populationDescription": "All participants as treated, consisting of all participants receiving the single dose of MK-8931 40 mg.",
                    "reportingStatus": "POSTED",
                    "paramType": "COUNT_OF_PARTICIPANTS",
                    "unitOfMeasure": "Participants",
                    "timeFrame": "Up to 14 days following MK-8931 40 mg administration.",
                    "groups": [
                        {
                            "id": "OG000",
                            "title": "Part I: MK-8931 40 mg in Moderate HI Participants",
                            "description": "Single oral dose of MK-8931 (40 mg tablet) in participants with moderate HI in fasted state (Part I)"
                        },
                        {
                            "id": "OG001",
                            "title": "Part I: MK-8931 40 mg in Healthy Participants",
                            "description": "Single oral dose of MK-8931 (40 mg tablet) in healthy matched participants in fasted state (Part I)"
                        }
                    ],
                    "denoms": [
                        {
                            "units": "Participants",
                            "counts": [
                                {
                                    "groupId": "OG000",
                                    "value": "8"
                                },
                                {
                                    "groupId": "OG001",
                                    "value": "8"
                                }
                            ]
                        }
                    ],
                    "classes": [
                        {
                            "categories": [
                                {
                                    "measurements": [
                                        {
                                            "groupId": "OG000",
                                            "value": "1"
                                        },
                                        {
                                            "groupId": "OG001",
                                            "value": "0"
                                        }
                                    ]
                                }
                            ]
                        }
                    ]
                },
                {
                    "type": "SECONDARY",
                    "title": "Number of Participants Discontinuing Study Due to an Adverse Event",
                    "description": "The number of participants discontinuing study due to an AE was assessed. An AE is any unfavorable and unintended medical occurrence, symptom, or disease witnessed in a participant, regardless of whether or not a causal relationship with the study treatment can be demonstrated. Further, any worsening of a preexisting condition that is temporally associated with the use of the study treatment is also considered an AE.",
                    "populationDescription": "All participants as treated, consisting of all participants receiving the single dose of MK-8931 40 mg.",
                    "reportingStatus": "POSTED",
                    "paramType": "COUNT_OF_PARTICIPANTS",
                    "unitOfMeasure": "Participants",
                    "timeFrame": "Up to 14 days following MK-8931 40 mg administration.",
                    "groups": [
                        {
                            "id": "OG000",
                            "title": "Part I: MK-8931 40 mg in Moderate HI Participants",
                            "description": "Single oral dose of MK-8931 (40 mg tablet) in participants with moderate HI in fasted state (Part I)"
                        },
                        {
                            "id": "OG001",
                            "title": "Part I: MK-8931 40 mg in Healthy Participants",
                            "description": "Single oral dose of MK-8931 (40 mg tablet) in healthy matched participants in fasted state (Part I)"
                        }
                    ],
                    "denoms": [
                        {
                            "units": "Participants",
                            "counts": [
                                {
                                    "groupId": "OG000",
                                    "value": "8"
                                },
                                {
                                    "groupId": "OG001",
                                    "value": "8"
                                }
                            ]
                        }
                    ],
                    "classes": [
                        {
                            "categories": [
                                {
                                    "measurements": [
                                        {
                                            "groupId": "OG000",
                                            "value": "1"
                                        },
                                        {
                                            "groupId": "OG001",
                                            "value": "0"
                                        }
                                    ]
                                }
                            ]
                        }
                    ]
                }
            ]
        },
        "adverseEventsModule": {
            "frequencyThreshold": "0",
            "timeFrame": "Up to 14 days following MK-8931 40 mg administration.",
            "eventGroups": [
                {
                    "id": "EG000",
                    "title": "Part I: MK-8931 40 mg in Moderate HI Participants",
                    "description": "Single oral dose of MK-8931 (40 mg tablet) in participants with moderate HI in fasted state (Part I)",
                    "deathsNumAffected": 0,
                    "deathsNumAtRisk": 8,
                    "seriousNumAffected": 1,
                    "seriousNumAtRisk": 8,
                    "otherNumAffected": 0,
                    "otherNumAtRisk": 8
                },
                {
                    "id": "EG001",
                    "title": "Part I: MK-8931 40 mg in Healthy Participants",
                    "description": "Single oral dose of MK-8931 (40 mg tablet) in healthy matched participants in fasted state (Part I)",
                    "deathsNumAffected": 0,
                    "deathsNumAtRisk": 8,
                    "seriousNumAffected": 0,
                    "seriousNumAtRisk": 8,
                    "otherNumAffected": 0,
                    "otherNumAtRisk": 8
                }
            ],
            "seriousEvents": [
                {
                    "term": "Chronic obstructive pulmonary disease",
                    "organSystem": "Respiratory, thoracic and mediastinal disorders",
                    "sourceVocabulary": "MedDRA 20.0",
                    "assessmentType": "SYSTEMATIC_ASSESSMENT",
                    "stats": [
                        {
                            "groupId": "EG000",
                            "numEvents": 1,
                            "numAffected": 1,
                            "numAtRisk": 8
                        },
                        {
                            "groupId": "EG001",
                            "numEvents": 0,
                            "numAffected": 0,
                            "numAtRisk": 8
                        }
                    ]
                }
            ]
        },
        "moreInfoModule": {
            "certainAgreement": {
                "piSponsorEmployee": false,
                "restrictionType": "OTHER",
                "restrictiveAgreement": true,
                "otherDetails": "The Sponsor must have the opportunity to review all proposed abstracts, manuscripts or presentations regarding this trial 45 days prior to submission for publication/presentation. Any information identified by the Sponsor as confidential must be deleted prior to submission; this confidentiality does not include efficacy and safety results. Sponsor review can be expedited to meet publication timelines."
            },
            "pointOfContact": {
                "title": "Senior Vice President, Global Clinical Development",
                "organization": "Merck Sharp & Dohme Corp",
                "email": "ClinicalTrialsDisclosure@merck.com",
                "phone": "1-800-672-6372"
            }
        }
    },
    "target_category": "disease-targeted small molecule",
    "drug": [
        "verubecestat (MK-8931)"
    ],
    "placebo": [],
    "explanation_target": [
        "Reason: The trial tests single-dose pharmacokinetics of verubecestat (MK-8931) in subjects with hepatic insufficiency. Verubecestat is a small-molecule inhibitor of BACE1 (\u03b2\u2011site APP\u2011cleaving enzyme 1) developed to reduce production of \u03b2\u2011amyloid, i.e., it targets Alzheimer\u2019s disease pathology rather than providing symptomatic cognitive enhancement or treating neuropsychiatric symptoms. \ue200cite\ue202turn0search2\ue202turn0search5\ue201",
        "Act: Key extracted details \u2014 drug: verubecestat (MK-8931); intervention type: oral small molecule BACE1 inhibitor; trial purpose here: PK comparison in mild/moderate hepatic insufficiency (single 40 mg dose, Part I and optional Part II). Matching to category: this fits 'disease-targeted small molecule' because the mechanism is BACE1 inhibition aimed at lowering amyloid production (disease-modifying mechanism). Trial listing and sponsor information confirm verubecestat's development by Merck and related clinical program context. \ue200cite\ue202turn0search4\ue202turn0search3\ue202turn0search1\ue201",
        "Reflect: The classification is consistent with the description and definitions \u2014 the study is a PK/safety study (not an efficacy or symptomatic treatment trial) but the drug\u2019s mechanism is disease-targeted (amyloid pathway) and it is a small molecule, so 'disease-targeted small molecule' is the appropriate category. Note: the specific trial described is a pharmacokinetic study (no placebo mentioned in this PK protocol), and separate efficacy trials of verubecestat have been conducted/terminated by Merck. \ue200cite\ue202turn0search0\ue202turn0search1\ue201"
    ],
    "agent_type": "A) Amyloid beta",
    "explanation_agent": [
        "Reason: The investigational drug verubecestat (MK-8931) is a small-molecule inhibitor of BACE1 (\u03b2\u2011site APP\u2011cleaving enzyme 1). BACE1 is the \u03b2\u2011secretase required for production of \u03b2\u2011amyloid (A\u03b2) peptides, so BACE1 inhibitors are designed to reduce A\u03b2 generation and therefore target the amyloid pathway/disease-modifying mechanism in Alzheimer's disease. \ue200cite\ue202turn0search5\ue202turn0search2\ue201",
        "Act: Key extracted details \u2014 drug: verubecestat (MK-8931); intervention type: oral small-molecule BACE1 inhibitor; trial described is a single-dose pharmacokinetic (PK) study in subjects with mild/moderate hepatic insufficiency (MK-8931-016 / NCT02910739). Because the drug\u2019s primary mechanism is upstream inhibition of A\u03b2 production, the most specific CADRO match is A) Amyloid beta. \ue200cite\ue202turn1search7\ue202turn0search4\ue201",
        "Reflect: The classification aligns with CADRO definitions \u2014 verubecestat's mechanism (BACE1 inhibition to lower A\u03b2) is an amyloid-targeted, disease-modifying approach rather than symptomatic or non-therapeutic. Although this particular protocol is a PK/safety study (not an efficacy trial), the molecule\u2019s biological target places it squarely in 'A) Amyloid beta'. I reviewed primary literature, Merck development communications, and clinical trial registry entries to confirm mechanism and the specific hepatic\u2011insufficiency PK study. \ue200cite\ue202turn0search1\ue202turn0search5\ue201",
        "Web search results used (most relevant sources):",
        "- Discovery / medicinal chemistry description of verubecestat as a BACE1 inhibitor. \ue200cite\ue202turn0search2\ue201",
        "- PubMed article showing verubecestat reduces CNS A\u03b2 in animals and humans. \ue200cite\ue202turn0search5\ue201",
        "- Merck press releases / program information on verubecestat (development and Phase 2/3 programs). \ue200cite\ue202turn0search1\ue202turn1search6\ue201",
        "- Clinical trial listing for the hepatic insufficiency PK study (MK-8931-016, NCT02910739). \ue200cite\ue202turn1search7\ue201",
        "- Alzforum summary page describing verubecestat (MK-8931) as a BACE inhibitor and amyloid-related program. \ue200cite\ue202turn0search4\ue201"
    ]
}